NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

INmune Bio Inc. (INMB) Stock Analysis

INmune Bio Inc. (INMB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INMB

$1.61

+$0.01 (+0.63%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INMB with… →

INMB Key Statistics

As of Oct 21, 2026
Trading
Open
$1.61
Previous Close
$1.60
Day's Range
1.60–1.69
52-Week Range
1.09–2.60
Volume
229.97K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.90
Valuation
Market Cap
$44.68M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.67
Financials (FY)
Revenue (FY)
$50.00K+257.14%
Net Income (FY)
−$45.93M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.75M
1-Year Return
−14.81%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
332.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INMB closed at $1.61, −14.81% over 1 year.

INmune Bio Inc. (INMB) has a market capitalization of $44.68M.

In fiscal 2025, INMB reported revenue of $50.00K.

INMB Stock Return by Calendar Year

INmune Bio Inc. (INMB) return since Feb 2019: what $10,000 became

1 year
$10,000 $8,519
−14.81%
5 years
$10,000 $839
−91.61%
Since Feb 2019
$10,000 $2,015
−79.85%

If you had invested $10,000 in INmune Bio Inc. (INMB) at the close on February 4, 2019, the earliest close on record here, it would have been worth $2,015 at the close on October 21, 2026: −79.85% in total, −18.76% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.21%
2025−66.60%
2024−58.53%
2023+77.60%
2022−37.84%
2021−40.77%
2020+196.90%
2019 (partial year)−27.41%

As of October 21, 2026.

INMB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$50.00K−$45.93M−91,866.0%
2024$14.00K−$42.08M−300,585.7%
2023$155.00K−$30.01M−19,360.0%
2022$374.00K−$27.30M−7,299.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$50.00K—−$30.87M−$45.93M−91,866.0%
2024$14.00K—−$42.64M−$42.08M−300,585.7%
2023$155.00K—−$29.74M−$30.01M−19,360.0%
2022$374.00K—−$25.95M−$27.30M−7,299.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values INmune Bio Inc. (INMB) at $44.68M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 21 employees.

The most recent close on file for INMB is $1.61, dated October 21, 2026. That is +$0.01 (+0.63%) against the previous close. Over the past 52 weeks the price has ranged from $1.09 to $2.60. The latest close sits 47.71% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $50.00K. Against the prior fiscal year total of $14.00K, that is a change of +257.14%. The same year closed with a net loss of $45.93M. Trailing earnings per share are −0.67.

Across the 4 fiscal years on file, revenue moves from $374.00K in 2022 to $50.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.9. Annualized volatility over the trailing 7 years is 94%. The trailing one-year total return is −14.81%. Across 5 years the annualized return works out at −39.08%.

Growth & Income

No dividend is on file for INMB.

The strongest complete calendar year on file is 2020 at +196.90%; the weakest is 2025 at −66.60%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +3.21% year to date.

Peer Comparison

INmune Bio Inc. (INMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
INmune Bio Inc. INMB $44.68M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. INmune Bio Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About INmune Bio Inc.

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Visit website →